<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>STAVUDINEÂ - stavudineÂ solutionÂ </strong><br>Boca Pharmacal, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use Stavudine safely and effectively. See full prescribing information for Stavudine.<br><br>Stavudine (Stavudine) SOLUTION for ORAL use.<br>Initial U.S. Approval: 1994</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"> WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span></span></h1>
<h1 class="Warning"><span class="Italics">Â  See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"> â€¢Â Â Â  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases. Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of stavudine and didanosine. (<a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">5.1</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have occurred when stavudine was part of a combination regimen that included didanosine. (<a href="#b5c4fd3f-a69f-4e3f-9282-ee9efa9de6fd">5.4</a>) </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta"> Dosage and Administration, Dosage Adjustment <br>(<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>) (<a href="#bbe60ec9-c8ac-4d86-ab1d-528cca350bd2">2.3</a>) â€“ removalÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  12/2010<br>Warnings and Precautions<br>Fat Redistribution (<a href="#bc72f11a-1711-4aa4-9f56-3955b5f82830">5.5</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  12/2010<br><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> (<a href="#b03f4f9e-1f9a-4f0b-8707-9eec9ef24581">5.6</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  11/2011 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"> WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span></span></h1>
<h1 class="Warning"><span class="Italics">Â  See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"> â€¢Â Â Â  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases. Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of stavudine and didanosine. (<a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">5.1</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have occurred when stavudine was part of a combination regimen that included didanosine. (<a href="#b5c4fd3f-a69f-4e3f-9282-ee9efa9de6fd">5.4</a>) </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"> Stavudine is a nucleoside reverse transcriptase inhibitor for use in combination with other antiretroviral agents for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV)-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#b24aca38-e51e-406b-8981-98fcdf86104a">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics">Recommended dosage for adults:</span><br>Â Â Â Â  â€¢Â Â Â  less than 60 kg: 30 mg every 12 hours (<a href="#b7747314-8ace-4f71-853e-5b83a24b0dbe">2.1</a>)<br>Â Â Â Â  â€¢Â Â Â  at least 60 kg: 40 mg every 12 hours (<a href="#b7747314-8ace-4f71-853e-5b83a24b0dbe">2.1</a>)  </p>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics">Recommended dosage for pediatric patients:</span><br>Â Â Â Â  â€¢Â Â Â  newborns from birth to 13 days old: 0.5 mg/kg every 12 hours (<a href="#b0dab30e-7529-4d74-b3cb-ce76d2a16612">2.2</a>)<br>Â Â Â Â  â€¢Â Â Â  at least 14 days old and weighing less than 30 kg: 1 mg/kg every 12 hours (<a href="#b0dab30e-7529-4d74-b3cb-ce76d2a16612">2.2</a>)<br>Â Â Â Â  â€¢Â Â Â  weighing at least 30 kg: adult dose (<a href="#b0dab30e-7529-4d74-b3cb-ce76d2a16612">2.2</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> Dose adjustment is recommended for CrCl â‰¤50 mL/min. (<a href="#b0012350-de9b-4f7d-a618-d4acf39aee36">2.3</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics">Oral solution:</span> Requires preparation by a pharmacist. (<a href="#be1ccff0-1067-486c-8495-168caeee5f09">2.4</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"> â€¢Â Â Â  Oral solution: 1 mg/mL following constitution (<a href="#b469e80d-9e6d-4e74-901f-edeb524da30b">3</a>, <a href="#b598d19a-a34f-4246-82a1-3a1bffdcde66">16.2</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"> Stavudine is contraindicated in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to stavudine or to any of the components of this product. (<a href="#bf69b3ce-3b54-48f4-aff2-83598da8c415">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span>/severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis:</span> Suspend treatment with stavudine in patients who develop clinical symptoms or signs with or without laboratory findings. (<a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">5.1</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics">Hepatic toxicity: </span>May be severe, fatal. Consider interruption or discontinuation. Avoid use in combination with didanosine and hydroxyurea. Risk of hepatic decompensation exists when used in combination with interferon and ribavirin; closely monitor and consider discontinuation of stavudine. (<a href="#b727942a-4e2a-49c7-9fba-7de5576dc644">5.2</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics"><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic symptoms</span>:</span> Motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, most often seen in the setting of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, may mimic Guillain-BarrÃ© syndrome; discontinue treatment. Monitor for <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, which can be severe; treatment discontinuation should be considered. (<a href="#b82de17f-b915-455b-80ac-9fbb33f49923">5.3</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>:</span> Suspend treatment, resume with particular caution and close monitoring and avoid use in combination with didanosine. (<a href="#b5c4fd3f-a69f-4e3f-9282-ee9efa9de6fd">5.4</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  Patients may develop redistribution/accumulation of body fat, monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>/<span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. Alternative antiretrovirals should be considered. (<a href="#bc72f11a-1711-4aa4-9f56-3955b5f82830">5.5</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  Patients may develop <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span>. (<a href="#b03f4f9e-1f9a-4f0b-8707-9eec9ef24581">5.6</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> â€¢Â Â Â  In adults, the most common adverse reactions are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#b98de034-c936-402b-965d-7e1f2943e14f">6.1</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  Adverse reactions in pediatric patients were consistent with those seen in adults. (<a href="#baccb639-d34a-4961-bd82-d7868ef67635">6.2</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta"> â€¢Â Â Â  Coadministration of stavudine with zidovudine should be avoided. (<a href="#bef5f7f2-e6a1-4c55-93fc-7a99a2955040">7</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  Coadministration of stavudine and doxorubicin or ribavirin should be undertaken with caution. (<a href="#bef5f7f2-e6a1-4c55-93fc-7a99a2955040">7</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics">Pregnancy:</span> Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received both didanosine and stavudine with other agents. This combination should be used with caution during pregnancy and only if the potential benefit clearly outweighs the potential risk to the fetus. Pregnancy registry available. (<a href="#b6950a45-f388-458f-b892-bcbecedb9292">8.1</a>) </p>
<p class="Highlighta"> â€¢Â Â Â  <span class="Italics">Nursing mothers</span> should be instructed not to breast-feed due to the potential for postnatal HIV transmission. (<a href="#bc30e93b-5506-4dac-b387-2137420865e3">8.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 10/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">BOXED WARNING 
</span></a></h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1Â  INDICATIONS &amp; USAGE 
</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION 
</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1Â Â Â  Recommended Adults Dosage
</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2Â Â Â  Recommended Pediatric Dosage
</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3Â Â Â  Dosage Adjustment
</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4Â Â Â  Method of Preparation for Oral Solution
</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS 
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4Â  CONTRAINDICATIONS 
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5Â  WARNINGS AND PRECAUTIONS 
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1Â Â Â  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2Â Â Â  Hepatic Toxicity
</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3Â Â Â  <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>
</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4Â Â Â  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>
</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5Â Â Â  Fat Redistribution
</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6Â Â Â  <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6Â  ADVERSE REACTIONS 
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1Â Â Â  Clinical Trial Experience in Adults
</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2Â Â Â  Clinical Trial Experience in Pediatric Patients 
</span></a></h2>
<h2><a href="#section-6.3" class="toc"><span class="Bold">6.3Â Â Â  Postmarketing Experience 
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7Â  DRUG INTERACTIONS 
</span></a></h1>
<h1><a href="#section-8" class="toc"><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS 
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold Italics">1Â  PREGNANCY 
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold Italics">3Â  NURSING MOTHERS 
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold Italics">4Â  PEDIATRIC USE 
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold Italics">5Â  GERIATRIC USE 
</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.6Â Â Â  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10Â  OVERDOSAGE 
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11Â  DESCRIPTION 
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12Â  CLINICAL PHARMACOLOGY 
</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold Italics">1Â  MECHANISM OF ACTION 
</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold Italics">3Â  PHARMACOKINETICS 
</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.4Â Â Â  Microbiology
</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13Â  NONCLINICAL TOXICOLOGY 
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold Italics">1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY 
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14Â  CLINICAL STUDIES 
</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16Â  HOW SUPPLIED 
</span></a></h1>
<h2><a href="#section-14.1" class="toc"><span class="Bold">16.2Â Â Â  Oral Solution
</span></a></h2>
<h1><a href="#section-15" class="toc"><span class="Bold">STORAGE AND HANDLING 
</span></a></h1>
<h1><a href="#section-16" class="toc"><span class="Bold">17Â  INFORMATION FOR PATIENTS 
</span></a></h1>
<h2><a href="#section-16.1" class="toc"><span class="Bold">17.1Â Â Â  General
</span></a></h2>
<h2><a href="#section-16.2" class="toc"><span class="Bold">17.2Â Â Â  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>
</span></a></h2>
<h2><a href="#section-16.3" class="toc"><span class="Bold">17.3Â Â Â  Hepatic Toxicity
</span></a></h2>
<h2><a href="#section-16.4" class="toc"><span class="Bold">17.4Â Â Â  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>
</span></a></h2>
<h2><a href="#section-16.5" class="toc"><span class="Bold">17.5Â Â Â  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>
</span></a></h2>
<h2><a href="#section-16.6" class="toc"><span class="Bold">17.6Â Â Â  Fat Redistribution
</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1><span class="Bold">BOXED WARNING 
</span></h1>
<p class="First"></p>
<p></p>
<p></p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals. Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of <span class="Italics">stavudine</span> and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk [see <span class="Italics"><a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">Warnings and Precautions (5.1)</a></span>].</p>
<p>Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have occurred during therapy when stavudine was part of a combination regimen that included didanosine in both treatment-naive and treatment-experienced patients, regardless of degree of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> [see <span class="Italics"><a href="#b5c4fd3f-a69f-4e3f-9282-ee9efa9de6fd">Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b24aca38-e51e-406b-8981-98fcdf86104a"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1Â  INDICATIONS &amp; USAGE 
</span></h1>
<p class="First"></p>
<p>Stavudine, in combination with other antiretroviral agents, is indicated for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV)-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> [see <span class="Italics"><a href="#b1923ae3-d6df-4698-8a84-21488616f7e1">Clinical Studies (14)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b39e7b8f-3af1-45b8-af2e-97778c73f46a"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION 
</span></h1>
<p class="First"></p>
<p></p>
<p></p>
<p></p>
<p>The interval between doses of stavudine should be 12 hours. Stavudine may be taken with or without food.</p>
<div class="Section">
<a name="b7747314-8ace-4f71-853e-5b83a24b0dbe"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1Â Â Â  Recommended Adults Dosage
</span></h2>
<p class="First">The recommended adult dosage is based on body weight as follows:</p>
<p>â€¢Â Â Â  For patients weighing less than 60 kg: 30 mg every 12 hours.</p>
<p>â€¢Â Â Â  For patients weighing at least 60 kg: 40 mg every 12 hours.</p>
</div>
<div class="Section">
<a name="b0dab30e-7529-4d74-b3cb-ce76d2a16612"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2Â Â Â  Recommended Pediatric Dosage
</span></h2>
<p class="First">â€¢Â Â Â  For newborns from birth to 13 days old: 0.5 mg/kg given every 12 hours.</p>
<p>â€¢Â Â Â  For pediatric patients at least 14 days old and weighing less than 30 kg: 1 mg/kg given every 12 hours.</p>
<p>â€¢Â Â Â  For pediatric patients weighing at least 30 kg: use the recommended adult dosage.</p>
</div>
<div class="Section">
<a name="b0012350-de9b-4f7d-a618-d4acf39aee36"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3Â Â Â  Dosage Adjustment
</span></h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><span class="Bold"><br></span><span class="Italics">Adult Patients:</span> Stavudine may be administered to adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> with an adjustment in dosage as shown in Table 1.</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="3" valign="middle"><span class="Bold">Table 1: Recommended Dosage Adjustment for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"> Creatinine Clearance<br>(mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"> Recommended Stavudine Dose by Patient Weight</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"> At least 60 kg</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"> Less than 60 kg</td>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Toprule" align="left" colspan="3" valign="top"> * Administered after the completion of hemodialysis on dialysis days and at the same time of day on non-dialysis days. </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">greater than 50</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">40 mg every 12 hours</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">30 mg every 12 hours</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">26-50</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">20 mg every 12 hours</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">15 mg every 12 hours</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">10-25</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">20 mg every 24 hours</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">15 mg every 24 hours</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Hemodialysis</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">20 mg every 24 hours<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">15 mg every 24 hours<span class="Sup">*</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Pediatric Patients:</span> Since urinary excretion is also a major route of elimination of stavudine in pediatric patients, the clearance of stavudine may be altered in children with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. There are insufficient data to recommend a specific dose adjustment of stavudine in this patient population.</p>
</div>
<div class="Section">
<a name="be1ccff0-1067-486c-8495-168caeee5f09"></a><a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4Â Â Â  Method of Preparation for Oral Solution
</span></h2>
<p class="First">Prior to dispensing, the pharmacist must constitute the dry powder with purified water to a concentration of 1 mg stavudine per mL of solution, as follows:</p>
<p>1.Â  Add 200 mL of purified water to the container.</p>
<p>2.Â  Shake container vigorously until the powder dissolves completely. Constitution in this way produces 200 mL (deliverable volume) of 1 mg/mL stavudine solution. The solution may appear slightly hazy.</p>
<p>3.Â  Dispense solution in original container with measuring cup provided. Instruct patient to shake the container vigorously prior to measuring each dose and to store the tightly closed container in a refrigerator, 2Â°C to 8Â°C (36Â°F to 46Â°F). Discard any unused portion after 30 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="b469e80d-9e6d-4e74-901f-edeb524da30b"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS 
</span></h1>
<p class="First"></p>
<p>Stavudine for oral solution is a dye-free, fruit-flavored powder that provides 1 mg of stavudine per milliliter solution after constitution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="bf69b3ce-3b54-48f4-aff2-83598da8c415"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4Â  CONTRAINDICATIONS 
</span></h1>
<p class="First"></p>
<p>Stavudine is contraindicated in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to stavudine or to any of the components contained in the formulation.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="be38eb23-c790-452c-a1f4-68fb5969a7ca"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5Â  WARNINGS AND PRECAUTIONS 
</span></h1>
<p class="First"></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p></p>
<div class="Section">
<a name="b479dcdf-9432-4e0d-827d-0a8dad4e6934"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1Â Â Â  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis
</span></h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals.</span> Although relative rates of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have not been assessed in prospective well-controlled trials, longitudinal cohort and retrospective studies suggest that this infrequent event may be more often associated with antiretroviral combinations containing stavudine. Female gender, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and prolonged nucleoside exposure may be risk factors. Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk [see <span class="Italics"><a href="#b6950a45-f388-458f-b892-bcbecedb9292">Use in Specific Populations (8.1)</a></span>].</p>
<p>Particular caution should be exercised when administering stavudine to any patient with known risk factors for liver disease; however, cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have also been reported in patients with no known risk factors. Generalized <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, digestive symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and unexplained <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>); respiratory symptoms (<span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>); or <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span>, including motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> [see <span class="Italics"><a href="#b82de17f-b915-455b-80ac-9fbb33f49923">Warnings and Precautions (5.3)</a></span>] might be indicative of the development of symptomatic hyperlactatemia or <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis syndrome</span>.</p>
<p>Treatment with stavudine should be suspended in any patient who develops clinical or laboratory findings suggestive of symptomatic hyperlactatemia, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations). Permanent discontinuation of stavudine should be considered for patients with confirmed <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>.</p>
</div>
<div class="Section">
<a name="b727942a-4e2a-49c7-9fba-7de5576dc644"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2Â Â Â  Hepatic Toxicity
</span></h2>
<p class="First">The safety and efficacy of stavudine have not been established in HIV-infected patients with significant underlying liver disease. During combination antiretroviral therapy, patients with preexisting liver dysfunction, including <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>, have an increased frequency of liver function abnormalities, including severe and potentially fatal hepatic adverse events, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.</p>
<p>Hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided. [See <span class="Italics"><a href="#b6ebb38a-2bdd-4ea4-871a-cd132f76279d">Adverse Reactions (6)</a></span>.]</p>
<p><span class="Bold Italics">Use with Interferon and Ribavirin-Based Regimens</span><br><span class="Italics">In vitro</span> studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as stavudine. Although no evidence of a pharmacokinetic or pharmacodynamic (eg, loss of HIV-1/HCV virologic suppression) interaction was seen when ribavirin was coadministered with stavudine in HIV-1/HCV co-infected patients [see <span class="Italics"><a href="#bef5f7f2-e6a1-4c55-93fc-7a99a2955040">Drug Interactions (7)</a></span>], <span class="Bold">hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon and ribavirin</span>. Patients receiving interferon with or without ribavirin and stavudine should be closely monitored for treatment-associated toxicities, especially hepatic decompensation. Discontinuation of stavudine should be considered as medically appropriate. Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (eg, Child-Pugh &gt;6) (see <span class="Bold">the full prescribing information for interferon and ribavirin</span>).</p>
</div>
<div class="Section">
<a name="b82de17f-b915-455b-80ac-9fbb33f49923"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3Â Â Â  <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>
</span></h2>
<p class="First">Motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> has been reported rarely in patients receiving combination antiretroviral therapy including stavudine. Most of these cases occurred in the setting of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. The evolution of motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> may mimic the clinical presentation of Guillain-BarrÃ© syndrome (including <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>). If motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> develops, stavudine should be discontinued. Symptoms may continue or worsen following discontinuation of therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">Peripheral sensory neuropathy</span>, manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the hands or feet, has been reported in patients receiving stavudine therapy. <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, which can be severe, is dose related and occurs more frequently in patients with advanced HIV-1 disease, a history of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, or in patients receiving other drugs that have been associated with <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, including didanosine [see <span class="Italics"><a href="#b6ebb38a-2bdd-4ea4-871a-cd132f76279d">Adverse Reactions (6)</a></span>].</p>
<p>Patients should be monitored for the development of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. Stavudine-related <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> may resolve if therapy is withdrawn promptly. If <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> develops permanent discontinuation of stavudine should be considered. In some cases, symptoms may worsen temporarily following discontinuation of therapy.</p>
</div>
<div class="Section">
<a name="b5c4fd3f-a69f-4e3f-9282-ee9efa9de6fd"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4Â Â Â  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>
</span></h2>
<p class="First">Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have occurred during therapy when stavudine was part of a combination regimen that included didanosine in both treatment-naive and treatment-experienced patients, regardless of degree of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. The combination of stavudine and didanosine and any other agents that are toxic to the pancreas should be suspended in patients with suspected <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Reinstitution of stavudine after a confirmed diagnosis of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> should be undertaken with particular caution and close patient monitoring; avoid use in combination with didanosine.</p>
</div>
<div class="Section">
<a name="bc72f11a-1711-4aa4-9f56-3955b5f82830"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5Â Â Â  Fat Redistribution
</span></h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy.</p>
<p>In randomized controlled trials of treatment-naive patients, clinical <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> developed in a higher proportion of patients treated with stavudine compared to other nucleosides (tenofovir or abacavir). Dual energy x-ray absorptiometry (DEXA) scans demonstrated overall limb fat loss in stavudine-treated patients compared to limb fat gain or no gain in patients treated with other nucleosides (abacavir, tenofovir, or zidovudine). The incidence and severity of <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> are cumulative over time with stavudine-containing regimens. In clinical trials, switching from stavudine to other nucleosides (tenofovir or abacavir) resulted in increases in limb fat with modest to no improvements in clinical <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>. Patients receiving stavudine should be monitored for symptoms or signs of <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> and questioned about body changes related to <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. Given the potential risks of using stavudine including <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, a benefit-risk assessment for each patient should be made and an alternative antiretroviral should be considered.</p>
</div>
<div class="Section">
<a name="b03f4f9e-1f9a-4f0b-8707-9eec9ef24581"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6Â Â Â  <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including stavudine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics"><span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis jiroveci pneumonia</span></span> (PCP), or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b6ebb38a-2bdd-4ea4-871a-cd132f76279d"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6Â  ADVERSE REACTIONS 
</span></h1>
<p class="First"></p>
<p></p>
<p>The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis [see <span class="Italics"><a href="#bddfcc84-1234-4ca2-96e4-b54adc56f9ff">Boxed Warning</a></span> and <span class="Italics"><a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">Warnings and Precautions (5.1)</a></span>]</li>
<li>hepatic toxicity [see <span class="Italics"><a href="#b727942a-4e2a-49c7-9fba-7de5576dc644">Warnings and Precautions (5.2)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> and motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> [see <span class="Italics"><a href="#b82de17f-b915-455b-80ac-9fbb33f49923">Warnings and Precautions (5.3)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> [see <span class="Italics"><a href="#bddfcc84-1234-4ca2-96e4-b54adc56f9ff">Boxed Warning</a></span> and <span class="Italics"><a href="#b5c4fd3f-a69f-4e3f-9282-ee9efa9de6fd">Warnings and Precautions (5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>/<span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> [see <span class="Italics"><a href="#bc72f11a-1711-4aa4-9f56-3955b5f82830">Warnings and Precautions (5.5)</a></span>]</li>
</ul>
<p>When stavudine is used in combination with other agents with similar toxicities, the incidence of adverse reactions may be higher than when stavudine is used alone.</p>
<div class="Section">
<a name="b98de034-c936-402b-965d-7e1f2943e14f"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1Â Â Â  Clinical Trial Experience in Adults
</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Selected adverse reactions that occurred in adult patients receiving stavudine in a controlled monotherapy study (Study AI455-019) are provided in Table 2.</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="3" valign="bottom">
<span class="Bold">Table 2: Selected Adverse Reactions in Study AI455-019</span><span class="Bold"><span class="Sup">a</span></span><span class="Bold"> (Monotherapy)</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percent (%)</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Stavudine</span><span class="Bold"><span class="Sup">b</span></span><span class="Bold"><br></span><span class="Bold">(40 mg twice daily)</span><span class="Bold"><br></span><span class="Bold">(n=412)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Zidovudine</span><span class="Bold"><br></span><span class="Bold">(200 mg 3 times daily)</span><span class="Bold"><br></span><span class="Bold">(n=402)</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" valign="top">
<span class="Sup">a</span> The incidences reported included all severity grades and all reactions regardless of causality. </td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top">
<span class="Sup">b</span> Median duration of stavudine therapy = 79 weeks, median duration of zidovudine therapy = 53 weeks. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">54</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">49</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">44</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Peripheral <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>/<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">52</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">39</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">35</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">39</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">44</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> was observed in 3 of the 412 adult patients who received stavudine in study AI455-019.</p>
<p>Selected adverse reactions that occurred in antiretroviral-naive adult patients receiving stavudine from two controlled combination studies are provided in Table 3.</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">Table 3: Selected Adverse Reactions</span><span class="Bold"><span class="Sup">a</span></span><span class="Bold"> in START 1 and START 2</span><span class="Bold"><span class="Sup">b</span></span><span class="Bold"> Studies (Combination Therapy)</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle"><span class="Bold">Percent (%) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">START 1 </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle">
<span class="Bold">START 2</span><span class="Bold"><span class="Sup">b</span></span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine + lamivudine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n = 100</span><span class="Bold"><span class="Sup">c</span></span><span class="Bold">)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Zidovudine + lamivudine + indinavir (n=102)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine + didanosine + indinavir </span><span class="Bold"><br></span><span class="Bold">(n = 102</span><span class="Bold"><span class="Sup">c</span></span><span class="Bold">)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Zidovudine + lamivudine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n = 103)</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" valign="top">
<span class="Sup">a</span> The incidences reported included all severity grades and all reactions regardless of causality. </td></tr>
<tr><td align="left" colspan="5" valign="top">
<span class="Sup">b</span> START 2 compared two triple-combination regimens in 205 treatment-naÃ¯ve patients. Patients received either Stavudine (40 mg twice daily) plus didanosine plus indinavir or zidovudine plus lamivudine plus indinavir. </td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Sup">c</span> Duration of stavudine therapy=48 weeks. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">43</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">63</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">53</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">67</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">34</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">45</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">39</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">26</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">46</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">37</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">33</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">35</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Peripheral <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>/Neurapathy</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10</td>
</tr>
</tbody>
</table>
<p>Selected laboratory abnormalities reported in a controlled monotherapy study (Study AI455-019) are provided in Table 4.</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="bottom">
<span class="Bold">Table 4: Selected Laboratory Abnormalities in Study AI455-019</span><span class="Bold"><span class="Sup">a,b</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"><span class="Bold">Parameter </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Percent(%) </span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine</span><span class="Bold"><br></span><span class="Bold">(40 mg twice daily)</span><span class="Bold"><br></span><span class="Bold">(n = 412) </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Zidovudine</span><span class="Bold"><br></span><span class="Bold">(200 mg 3 times daily)</span><span class="Bold"><br></span><span class="Bold">(n = 402) </span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" valign="top">
<span class="Sup">a</span> Data presented for patients for whom laboratory evaluations were performed. </td></tr>
<tr><td align="left" colspan="3" valign="top">
<span class="Sup">b</span> Median duration of stavudine therapy = 79 weeks; median duration of zidovudine therapy = 53 weeks. </td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"> ULN = upper limit of normal. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)<br>(&gt; 5.0 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">ALT (SGPT)<br>(&gt; 5.0 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Amylase<br>(â‰¥ 1.4 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13</td>
</tr>
</tbody>
</table>
<p>Selected laboratory abnormalities reported in two controlled combination studies are provided in Tables 5 and 6.</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="5" valign="top"><span class="Bold">Table 5: Selected Laboratory Abnormalities in START 1 and START 2 Studies (Grades 3â€“4) </span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="bottom"><span class="Bold">Parameter</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle"><span class="Bold">Percent (%) </span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">START 1 </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">START 2</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine + lamivudine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n= 100)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Zidovudine + lamivudine + indinavir </span><span class="Bold"><br></span><span class="Bold">(n= 102)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine + didanosine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n= 102)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Zidovudine + lamivudine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n=103)</span>
</td>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Toprule" align="left" colspan="5" valign="top"> ULN = upper limit of normal. </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Bilirubin<br>(&gt;2.6 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)<br>(&gt;5 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">ALT (SGPT)<br>(&gt;5 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">GGT<br>(&gt;5 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Lipase<br>(&gt;2 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Amylase<br>(&gt;2 x ULN)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2</td>
</tr>
</tbody>
</table>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="5" valign="top"><span class="Bold">Table 6: Selected Laboratory Abnormalities in START 1 and START 2 Studies (All Grades)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="bottom"><span class="Bold">Parameter </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle"><span class="Bold">Percent (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">START 1</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">START 2</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine + lamivudine + indinavir </span><span class="Bold"><br></span><span class="Bold">(n= 100)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Zidovudine + lamivudine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n=102) </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine + didanosine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n=102) </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Zidovudine + lamivudine + indinavir</span><span class="Bold"><br></span><span class="Bold">(n=103) </span>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Total Bilirubin</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">65</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">60</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">68</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">55</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">53</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">ALT (SGPT)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">GGT</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">28</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Lipase</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">27</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">26</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Amylase</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">31</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="baccb639-d34a-4961-bd82-d7868ef67635"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2Â Â Â  Clinical Trial Experience in Pediatric Patients 
</span></h2>
<p class="First">Adverse reactions and serious laboratory abnormalities reported in pediatric patients from birth through adolescence during clinical trials were similar in type and frequency to those seen in adult patients. [See <span class="Italics"><a href="#b83a25a6-c42b-4241-81a9-dfc79f10b570">Use in Specific Populations (8.4).</a></span>]</p>
</div>
<div class="Section">
<a name="section-6.3"></a><p></p>
<h2><span class="Bold">6.3Â Â Â  Postmarketing Experience 
</span></h2>
<p class="First">The following adverse reactions have been identified during postmarketing use of stavudine. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to their seriousness, frequency of reporting, causal connection to stavudine, or a combination of these factors.</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and redistribution/accumulation of body fat [see <span class="Italics"><a href="#bc72f11a-1711-4aa4-9f56-3955b5f82830">Warnings and Precautions (5.5)</a></span>].</p>
<p><span class="Italics">Digestive Disorders</span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p><span class="Italics">Exocrine Gland Disorders</span>: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, including fatal cases [see <span class="Italics"><a href="#b5c4fd3f-a69f-4e3f-9282-ee9efa9de6fd">Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="Italics">Hematologic Disorders:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>.</p>
<p><span class="Italics">Liver</span>: symptomatic hyperlactatemia/<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> [see <span class="Italics"><a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">Warnings and Precautions (5.1)</a></span>], <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">Metabolic Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>, <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> [see <span class="Italics"><a href="#bc72f11a-1711-4aa4-9f56-3955b5f82830">Warnings and Precautions (5.5)</a></span>], <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, severe motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> (most often reported in the setting of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>) [see <span class="Italics"><a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">Warnings and Precautions (5.1</a></span><span class="Italics">, </span><span class="Italics"><a href="#b82de17f-b915-455b-80ac-9fbb33f49923">5.3</a></span><span class="Italics">)</span>].</p>
<p><span class="Bold">Use with Didanosine- and Hydroxyurea-Based Regimens</span></p>
<p>When stavudine is used in combination with other agents with similar toxicities, the incidence of these toxicities may be higher than when stavudine is used alone. Thus, patients treated with stavudine in combination with didanosine, with or without hydroxyurea, may be at increased risk for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and hepatotoxicity, which may be fatal, and severe <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> [see <span class="Italics"><a href="#be38eb23-c790-452c-a1f4-68fb5969a7ca">Warnings and Precautions (5)</a></span>]. The combination of stavudine and hydroxyurea, with or without didanosine, should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="bef5f7f2-e6a1-4c55-93fc-7a99a2955040"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7Â  DRUG INTERACTIONS 
</span></h1>
<p class="First"></p>
<p></p>
<p>Stavudine is unlikely to interact with drugs metabolized by cytochrome P450 isoenzymes.</p>
<p><span class="Italics">Zidovudine:</span> Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. Therefore, use of zidovudine in combination with stavudine should be avoided.</p>
<p><span class="Italics">Doxorubicin: In vitro</span> data indicate that the phosphorylation of stavudine is inhibited at relevant concentrations by doxorubicin. The clinical significance of this interaction is unknown; therefore, concomitant use of stavudine with doxorubicin should be undertaken with caution.</p>
<p><span class="Italics">Ribavirin: In vitro</span> data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. The clinical significance of the interaction with stavudine is unknown; therefore, concomitant use of stavudine with ribavirin should be undertaken with caution. No pharmacokinetic (eg, plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (eg, loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n=18), stavudine (n=10), or zidovudine (n=6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see <span class="Italics"><a href="#b727942a-4e2a-49c7-9fba-7de5576dc644">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS 
</span></h1>
<p class="First"></p>
<p></p>
<div class="Section" data-sectionCode="42228-7">
<a name="b6950a45-f388-458f-b892-bcbecedb9292"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold Italics">1Â  PREGNANCY 
</span></h2>
<p class="First">Pregnancy Category C<br>Reproduction studies have been performed in rats and rabbits with exposures (based on C<span class="Sub">max</span>) up to 399 and 183 times, respectively, of that seen at a clinical dosage of 1 mg/kg/day and have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. The incidence in fetuses of a common skeletal variation, unossified or incomplete ossification of sternebra, was increased in rats at 399 times human exposure, while no effect was observed at 216 times human exposure. A slight post-implantation loss was noted at 216 times the human exposure with no effect noted at approximately 135 times the human exposure. An increase in early rat neonatal mortality (birth to 4 days of age) occurred at 399 times the human exposure, while survival of neonates was unaffected at approximately 135 times the human exposure. A study in rats showed that stavudine is transferred to the fetus through the placenta. The concentration in fetal tissue was approximately one-half the concentration in maternal plasma. Animal reproduction studies are not always predictive of human response.</p>
<p>There are no adequate and well-controlled studies of stavudine in pregnant women. Stavudine should be used during pregnancy only if the potential benefit justifies the potential risk.</p>
<p>Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. It is unclear if pregnancy augments the risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>/<span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> syndrome reported in nonpregnant individuals receiving nucleoside analogues [see <span class="Italics"><a href="#bddfcc84-1234-4ca2-96e4-b54adc56f9ff">Boxed Warning</a></span> and <span class="Italics"><a href="#b479dcdf-9432-4e0d-827d-0a8dad4e6934">Warnings and Precautions (5.1)</a></span>]. <span class="Bold">The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk</span>.</p>
<p>Healthcare providers caring for HIV-infected pregnant women receiving stavudine should be alert for early diagnosis of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>/<span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> syndrome.</p>
<p><span class="Bold">Antiretroviral Pregnancy Registry</span>: To monitor maternal-fetal outcomes of pregnant women exposed to stavudine and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="bc30e93b-5506-4dac-b387-2137420865e3"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold Italics">3Â  NURSING MOTHERS 
</span></h2>
<p class="First"><span class="Bold">The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV</span>. Studies in lactating rats demonstrated that stavudine is excreted in milk. Although it is not known whether stavudine is excreted in human milk, there exists the potential for adverse effects from stavudine in nursing infants. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breastfeed if they are receiving stavudine.</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="b83a25a6-c42b-4241-81a9-dfc79f10b570"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold Italics">4Â  PEDIATRIC USE 
</span></h2>
<p class="First">Use of stavudine in pediatric patients from birth through adolescence is supported by evidence from adequate and well-controlled studies of stavudine in adults with additional pharmacokinetic and safety data in pediatric patients [see <span class="Italics"><a href="#b0dab30e-7529-4d74-b3cb-ce76d2a16612">Dosage and Administration (2.2)</a></span> and <span class="Italics"><a href="#baccb639-d34a-4961-bd82-d7868ef67635">Adverse Reactions (6.2)</a></span>].</p>
<p>Adverse reactions and laboratory abnormalities reported to occur in pediatric patients in clinical studies were generally consistent with the safety profile of stavudine in adults. These studies include ACTG 240, where 105 pediatric patients ages 3 months to 6 years received stavudine 2 mg/kg/day for a median of 6.4 months; a controlled clinical trial where 185 newborns received stavudine 2 mg/kg/day either alone or in combination with didanosine from birth through 6 weeks of age; and a clinical trial where 8 newborns received stavudine 2 mg/kg/day in combination with didanosine and nelfinavir from birth through 4 weeks of age.</p>
<p>Stavudine pharmacokinetics have been evaluated in 25 HIV-1-infected pediatric patients ranging in age from 5 weeks to 15 years and in weight from 2 to 43 kg after IV or oral administration of single doses and twice-daily regimens and in 30 HIV-1-exposed or -infected newborns ranging in age from birth to 4 weeks after oral administration of twice-daily regimens [see <span class="Italics"><a href="#bcddb69a-00a0-4596-97c5-b7e6b28af760">Clinical Pharmacology (12.3, Table 9</a></span>)].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="bfe9da68-7d84-4e22-8adf-aa2335c6e5e9"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold Italics">5Â  GERIATRIC USE 
</span></h2>
<p class="First">Clinical studies of stavudine did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Greater sensitivity of some older individuals to the effects of stavudine cannot be ruled out.</p>
<p>In a monotherapy Expanded Access Program for patients with advanced HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> or peripheral neuropathic symptoms were observed in 15 of 40 (38%) elderly patients receiving 40 mg twice daily and 8 of 51 (16%) elderly patients receiving 20 mg twice daily. Of the approximately 12,000 patients enrolled in the Expanded Access Program, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> or peripheral neuropathic symptoms developed in 30% of patients receiving 40 mg twice daily and 25% of patients receiving 20 mg twice daily. Elderly patients should be closely monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
<p>Stavudine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function. Dose adjustment is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics"><a href="#b0012350-de9b-4f7d-a618-d4acf39aee36">Dosage and Administration (2.3)</a></span>].</p>
</div>
<div class="Section">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.6Â Â Â  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></h2>
<p class="First">Data from two studies in adults indicated that the apparent oral clearance of stavudine decreased and the terminal elimination half-life increased as creatinine clearance decreased. Based on these observations, it is recommended that the stavudine dosage be modified in patients with reduced creatinine clearance and in patients receiving maintenance hemodialysis [see <span class="Italics"><a href="#b0012350-de9b-4f7d-a618-d4acf39aee36">Dosage and Administration (2.3)</a></span> and <span class="Italics"><a href="#bcddb69a-00a0-4596-97c5-b7e6b28af760">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10Â  OVERDOSAGE 
</span></h1>
<p class="First">Experience with adults treated with 12 to 24 times the recommended daily dosage revealed no acute toxicity. Complications of chronic overdosage include <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> and hepatic toxicity. Stavudine can be removed by hemodialysis; the mean Â± SD hemodialysis clearance of stavudine is 120 Â± 18 mL/min. Whether stavudine is eliminated by peritoneal dialysis has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11Â  DESCRIPTION 
</span></h1>
<p class="First">Stavudine (d4T) is a synthetic thymidine nucleoside analogue, active against the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1). The chemical name for stavudine is 2â€²,3â€²-didehydro-3â€²-deoxythymidine. Stavudine has the following structural formula:</p>
<div class="Figure"><img alt="a1ac2cfb-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=259fbf19-ad1a-424f-873a-ba12e42b9315&amp;name=a1ac2cfb-figure-01.jpg"></div>
<p>Stavudine is a white to off-white crystalline solid with the molecular formula C<span class="Sub">10</span>H<span class="Sub">12</span>N<span class="Sub">2</span>O<span class="Sub">4</span> and a molecular weight of 224.2. The solubility of stavudine at 23Â°C is approximately 83 mg/mL in water and 30 mg/mL in propylene glycol. The n-octanol/water partition coefficient of stavudine at 23Â°C is 0.144.</p>
<p>Powder for Oral Solution: Stavudine is available as a dye-free, fruit-flavored powder in bottles with child-resistant closures providing 200 mL of a 1 mg/mL stavudine oral solution upon constitution with water per label instructions. The powder for oral solution contains the following inactive ingredients: carboxymethyl cellulose sodium, mannitol, methylparaben, propylparaben, sodium saccharin, and strawberry cream flavour.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12Â  CLINICAL PHARMACOLOGY 
</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold Italics">1Â  MECHANISM OF ACTION 
</span></h2>
<p class="First">Stavudine is an antiviral drug [see <span class="Italics"><a href="#b0b9327e-959d-4a72-b685-1b56f9603b3b">Clinical Pharmacology (12.4)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="bcddb69a-00a0-4596-97c5-b7e6b28af760"></a><a name="section-11.2"></a><p></p>
<h2><span class="Bold Italics">3Â  PHARMACOKINETICS 
</span></h2>
<p class="First">The pharmacokinetics of stavudine have been evaluated in HIV-1-infected adult and pediatric patients (Tables 7, 8, and 9). Peak plasma concentrations (C<span class="Sub">max</span>) and area under the plasma concentration-time curve (AUC) increased in proportion to dose after both single and multiple doses ranging from 0.03 to 4 mg/kg. There was no significant accumulation of stavudine with repeated administration every 6, 8, or 12 hours.</p>
<p><span class="Bold">Absorption</span><br>Following oral administration, stavudine is rapidly absorbed, with peak plasma concentrations occurring within 1 hour after dosing. The systemic exposure to stavudine is the same following administration as capsules or solution. Steady-state pharmacokinetic parameters of stavudine in HIV-1-infected adults are shown in Table 7.</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="2" valign="top"><span class="Bold">Table 7: Steady-State Pharmacokinetic Parameters of Stavudine in HIV-1-Infected Adults </span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Parameter </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Stavudine 40 mg BID</span><span class="Bold"><br></span><span class="Bold">Mean Â± SD (n=8)</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="2" valign="top"> AUC<span class="Sub">0-24 </span>= Area under the curve over 24 hours. </td></tr>
<tr><td align="left" colspan="2" valign="top"> C<span class="Sub">max</span> = Maximum plasma concentration. </td></tr>
<tr class="Last"><td align="left" colspan="2" valign="top"> C<span class="Sub">min</span> = Trough or minimum plasma concentration. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">AUC<span class="Sub">0-24 </span>(ngâˆ™h/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2568 Â± 454</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">C<span class="Sub">max</span> (ng/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">536 Â± 146</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">C<span class="Sub">min</span> (ng/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8 Â± 9</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Distribution</span><br>Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 to 11.4 Î¼g/mL. Stavudine distributes equally between red blood cells and plasma. Volume of distribution is shown in Table 8.</p>
<p><span class="Bold">Metabolism</span><span class="Bold"><br></span>Metabolism plays a limited role in the clearance of stavudine. Unchanged stavudine was the major drug-related component circulating in plasma after an 80-mg dose of <span class="Sup">14</span>C-stavudine, while metabolites constituted minor components of the circulating radioactivity. Minor metabolites include oxidized stavudine, glucuronide conjugates of stavudine and its oxidized metabolite, and an <span class="Italics">N</span>-acetylcysteine conjugate of the ribose after glycosidic cleavage, suggesting that thymine is also a metabolite of stavudine.</p>
<p><span class="Bold">Elimination</span><br>Following an 80-mg dose of <span class="Sup">14</span>C-stavudine to healthy subjects, approximately 95% and 3% of the total radioactivity was recovered in urine and feces, respectively. Radioactivity due to parent drug in urine and feces was 73.7% and 62.0%, respectively. The mean terminal elimination half-life is approximately 2.3 hours following single oral doses. Mean renal clearance of the parent compound is approximately 272 mL/min, accounting for approximately 67% of the apparent oral clearance.</p>
<p>In HIV-1-infected patients, renal elimination of unchanged drug accounts for about 40% of the overall clearance regardless of the route of administration (Table 8). The mean renal clearance was about twice the average endogenous creatinine clearance, indicating active tubular secretion in addition to glomerular filtration.</p>
<table frame="void" width="650">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="3" valign="top">
<span class="Bold">Table 8: Pharmacokinetic Parameters of Stavudine in HIV-1-Infected Adults:</span><span class="Bold"><br></span><span class="Bold">Bioavailability, Distribution, and Clearance </span>
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Parameter </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Mean Â± SD </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">n </span></td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" valign="top">
<span class="Sup">a</span> Following 1-hour IV infusion. </td></tr>
<tr><td align="left" colspan="3" valign="top">
<span class="Sup">b</span> Following single oral dose. </td></tr>
<tr><td align="left" colspan="3" valign="top">
<span class="Sup">c</span> Assuming a body weight of 70 kg. </td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top">
<span class="Sup">d</span> Over 12â€“24 hours. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Oral bioavailability (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">86.4 Â± 18.2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">25</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Volume of distribution (L)<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">46 Â± 21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">44</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Totally body clearance (mL/min)<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">594Â± 164</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">44</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Apparent oral clearance (mL/min)<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">560 Â± 182<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">113</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Renal clearance (mL/min)<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">237 Â± 98</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">39</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Elimination half-life, IV dose (h)<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1.15 Â± 0.35</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">44</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Elimination half-life, oral dose (h)<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1.6 Â± 0.23</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">8</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Urinary recovery of stavudine (% of dose)<span class="Sup">a,d</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">42 Â± 14</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">39</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Italics">Pediatric</span><span class="Italics"><br></span>Pharmacokinetic parameters of stavudine in pediatric patients are presented in Table 9.</p>
<table frame="void" width="607">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="7" valign="top"><span class="Bold">Table 9: Pharmacokinetic Parameters (Mean Â± SD) of Stavudine in HIV-1-Exposed or-Infected Pediatric Patients </span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Parameter</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Ages 5 weeks to 15 years </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">n </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Ages 14 to 28 days </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">n </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Day of Birth </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">n</span></td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="7" valign="top">
<span class="Sup">a</span> Following 1-hour IV infusion. </td></tr>
<tr><td align="left" colspan="7" valign="top">
<span class="Sup">b</span> At median time of 2.5 hours (range 2â€“3 hours) following multiple oral doses. </td></tr>
<tr><td align="left" colspan="7" valign="top">
<span class="Sup">c</span> Following single oral dose. </td></tr>
<tr><td align="left" colspan="7" valign="top">
<span class="Sup">d</span> Over 8 hours. </td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"> ND = Not determined. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Oral bioavailability (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">76.9 Â± 31.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Volume of distribution (L/kg)<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.73 Â± 0.32</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Ratio of CSF: plasma concentrations (as %)<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">59 Â± 35</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Total body clearance (mL/min/kg)<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9.75 Â± 3.76</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Apparent oral clearance (mL/min/kg)<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13.75 Â± 4.29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11.52 Â± 5.93</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5.08 Â± 2.80</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Elimination half-life, IV dose (h)<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.11 Â± 0.28</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Elimination half-life, oral dose (h)<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.96 Â± 0.26</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.59 Â± 0.29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5.27 Â± 2.01</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Urinary recovery of stavudine<br>(% of dose)<span class="Sup">c,d</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">34 Â± 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ND</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><span class="Italics"><br></span>Data from two studies in adults indicated that the apparent oral clearance of stavudine decreased and the terminal elimination half-life increased as creatinine clearance decreased (see Table 10). C<span class="Sub">max</span> and T<span class="Sub">max</span> were not significantly altered by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The mean Â± SD hemodialysis clearance value of stavudine was 120 Â± 18 mL/min (n=12); the mean Â± SD percentage of the stavudine dose recovered in the dialysate, timed to occur between 2â€“6 hours post-dose, was 31 Â± 5%. Based on these observations, it is recommended that stavudine dosage be modified in patients with reduced creatinine clearance and in patients receiving maintenance hemodialysis [see <span class="Italics"><a href="#b0012350-de9b-4f7d-a618-d4acf39aee36">Dosage and Administration (2.3)</a></span>].</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">Table 10: Mean Â± SD Pharmacokinetic Parameter Values of Stavudine</span><span class="Bold"><span class="Sup">a</span></span><span class="Bold"> in Adults with Varying Degrees of Renal Function</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle"> Creatinine Clearance</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"> Hemodialysis Patients<span class="Sup">b</span><br>(n=11) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"> &gt;50 mL/min<br>(n=10) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"> 26-50 mL/min<br>(n=5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"> 9-25 mL/min<br>(n=5) </td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" valign="top">
<span class="Sup">a</span> Single 40-mg oral dose. </td></tr>
<tr><td align="left" colspan="5" valign="top">
<span class="Sup">b</span> Determined while patients were off dialysis. </td></tr>
<tr><td align="left" colspan="5" valign="top"> T<span class="Sub">Â½</span> = Terminal elimination half-life. </td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"> NA = Not applicable </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Creatinine clearance (mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">104 Â± 28</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">41 Â± 5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">17 Â± 3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">NA</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Apparent oral clearance (mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">335 Â± 57</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">191 Â± 39</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">116 Â± 25</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">105 Â± 17</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Renal clearance (mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">167 Â± 65</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">73 Â± 18</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">17 Â± 3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">NA</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">T<span class="Sub">1/2 </span>(h)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1.7 Â± 0.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3.5 Â± 2.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4.6 Â± 0.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">5.4 Â± 1.4</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><span class="Italics"><br></span>Stavudine pharmacokinetics were not altered in five non-HIV-infected patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> secondary to cirrhosis (Child-Pugh classification B or C) following the administration of a single 40-mg dose.</p>
<p><span class="Italics">Geriatric</span><span class="Italics"><br></span>Stavudine pharmacokinetics have not been studied in patients &gt;65 years of age. [See <span class="Italics"><a href="#bfe9da68-7d84-4e22-8adf-aa2335c6e5e9">Use in Specific Populations (8.5)</a></span>.]</p>
<p><span class="Italics">Gender</span><span class="Italics"><br></span>A population pharmacokinetic analysis of data collected during a controlled clinical study in HIV-1-infected patients showed no clinically important differences between males (n=291) and females (n=27).</p>
<p><span class="Italics">Race</span><span class="Italics"><br></span>A population pharmacokinetic analysis of data collected during a controlled clinical study in HIV-1-infected patients showed no clinically important differences between races (n=233 Caucasian, 39 African-American, 41 Hispanic, 1 Asian, and 4 other).</p>
<p><span class="Bold">Drug Interaction Studies</span><span class="Bold"><br></span>Stavudine does not inhibit the major cytochrome P450 isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4; therefore, it is unlikely that clinically significant drug interactions will occur with drugs metabolized through these pathways. Because stavudine is not protein-bound, it is not expected to affect the pharmacokinetics of protein-bound drugs.</p>
<p>Tables 11 and 12 summarize the effects on AUC and C<span class="Sub">max</span>, with a 95% confidence interval (CI) when available, following coadministration of stavudine with didanosine, lamivudine, and nelfinavir. No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed.</p>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">Table 11: Results of Drug Interaction Studies with Stavudine: Effects of Coadministered Drug on Stavudine Plasma AUC and C</span><span class="Bold"><span class="Sub">max</span></span><span class="Bold"> Values </span>
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"> Drug </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> Stavudine Dosage </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> n<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> AUC of Stavudine<br>(95% CI) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> C<span class="Sub">max</span> of Stavudine<br>(95% CI)</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" valign="top"> â†‘ Indicates increase. </td></tr>
<tr><td align="left" colspan="5" valign="top"> â†” Indicates no change, or mean increase or decrease of &lt;10%. </td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top">
<span class="Sup">a</span> HIV-1-infected patients. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Didanosine, 100 mg q12h for 4 days</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">40 mg q12h for 4 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†‘ 17%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Lamivudine, 150 mg single dose</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">40 mg single dose</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”<br>(92.7%-100.6%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†‘ 12%<br>(100.3-126.1%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Nelfinavir, 750mg q8h for 56 days</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">30-40 mg q12h for 56 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”</td>
</tr>
</tbody>
</table>
<table frame="void" width="590">
<thead>
<tr class="First"><td class="Botrule" align="left" colspan="5" valign="top">
<span class="Bold">Table 12: Results of Drug Interaction Studies with Stavudine: Effects of Stavudine on Coadministered Drug Plasma AUC and C</span><span class="Bold"><span class="Sub">max</span></span><span class="Bold"> Values</span>
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"> Drug </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> Stavudine Dosage</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> n<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> AUC of Coadministered Drug<br>(95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"> C<span class="Sub">max</span> of Coadministered Drug<br>(95% CI) </td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" valign="top"> â†” Indicates no change, or mean increase or decrease of &lt;10%. </td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top">
<span class="Sup">a</span> HIV-1-infected patients. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Didanosine, 100 mg q12h for 4 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40 mg q12h for 4 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Lamivudine, 150 mg single dose</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40 mg single dose</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”<br>(90.5-107.6%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”<br>(87.1-110.6%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Nelfinavir, 750 mg q8h for 56 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30-40 mg q12h for 56 days</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">â†”</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="b0b9327e-959d-4a72-b685-1b56f9603b3b"></a><a name="section-11.3"></a><p></p>
<h2><span class="Bold">12.4Â Â Â  Microbiology
</span></h2>
<p class="First"><span class="Bold">Mechanism of Action</span><span class="Bold"><br></span>Stavudine, a nucleoside analogue of thymidine, is phosphorylated by cellular kinases to the active metabolite stavudine triphosphate. Stavudine triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate thymidine triphosphate (K<span class="Sub">i</span>=0.0083 to 0.032 Î¼M) and by causing DNA chain termination following its incorporation into viral DNA. Stavudine triphosphate inhibits cellular DNA polymerases Î² and Î³ and markedly reduces the synthesis of mitochondrial DNA.</p>
<p><span class="Bold">Antiviral Activity in Cell Culture</span><span class="Bold"><br></span>The cell culture antiviral activity of stavudine was measured in peripheral blood mononuclear cells, monocytic cells, and lymphoblastoid cell lines. The concentration of drug necessary to inhibit HIV-1 replication by 50% (EC<span class="Sub">50</span>) ranged from 0.009 to 4 Î¼M against laboratory and clinical isolates of HIV-1. In cell culture, stavudine exhibited additive to antagonistic activity in combination with zidovudine. Stavudine in combination with either abacavir, didanosine, tenofovir, or zalcitabine exhibited additive to synergistic anti-HIV-1 activity. Ribavirin, at the 9â€“45 Î¼M concentrations tested, reduced the anti-HIV-1 activity of stavudine by 2.5- to 5-fold. The relationship between cell culture susceptibility of HIV-1 to stavudine and the inhibition of HIV-1 replication in humans has not been established.</p>
<p><span class="Bold">Resistance</span><span class="Bold"><br></span>HIV-1 isolates with reduced susceptibility to stavudine have been selected in cell culture (<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>-specific) and were also obtained from patients treated with stavudine. Phenotypic analysis of HIV-1 isolates from 61 patients receiving prolonged (6â€“29 months) stavudine monotherapy showed that post-therapy isolates from four patients exhibited EC<span class="Sub">50</span> values more than 4-fold (range 7- to 16-fold) higher than the average pretreatment susceptibility of baseline isolates. Of these, HIV-1 isolates from one patient contained the zidovudine-resistance-associated substitutions T215Y and K219E, and isolates from another patient contained the multiple-nucleoside-resistance-associated substitution Q151M. Mutations in the RT gene of HIV-1 isolates from the other two patients were not detected. The genetic basis for stavudine susceptibility changes has not been identified.</p>
<p><span class="Bold">Cross-resistance</span><span class="Bold"><br></span>Cross-resistance among HIV-1 reverse transcriptase inhibitors has been observed. Several studies have demonstrated that prolonged stavudine treatment can select and/or maintain thymidine analogue mutations (TAMs; M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) associated with zidovudine resistance. HIV-1 isolates with one or more TAMs exhibited reduced susceptibility to stavudine in cell culture. These TAMs are seen at a similar frequency with stavudine and zidovudine in virological treatment. The clinical relevance of these findings suggests that stavudine should be avoided in the presence of thymidine analogue mutations.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13Â  NONCLINICAL TOXICOLOGY 
</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold Italics">1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY 
</span></h2>
<p class="First">In 2-year carcinogenicity studies in mice and rats, stavudine was noncarcinogenic at doses which produced exposures (AUC) 39 and 168 times, respectively, human exposure at the recommended clinical dose. Benign and <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span> in mice and rats and malignant urinary bladder tumors in male rats occurred at levels of exposure 250 (mice) and 732 (rats) times human exposure at the recommended clinical dose.</p>
<p>Stavudine was not mutagenic in the Ames, <span class="Italics">E. coli</span> reverse mutation, or the CHO/HGPRT mammalian cell forward gene mutation assays, with and without metabolic activation. Stavudine produced positive results in the <span class="Italics">in vitro</span> human lymphocyte clastogenesis and mouse fibroblast assays, and in the <span class="Italics">in vivo</span> mouse micronucleus test. In the <span class="Italics">in vitro</span> assays, stavudine elevated the frequency of chromosome aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> (concentrations of 25 to 250 Î¼g/mL, without metabolic activation) and increased the frequency of transformed foci in mouse fibroblast cells (concentrations of 25 to 2500 Î¼g/mL, with and without metabolic activation). In the <span class="Italics">in vivo</span> micronucleus assay, stavudine was clastogenic in bone marrow cells following oral stavudine administration to mice at dosages of 600 to 2000 mg/kg/day for 3 days.</p>
<p>No evidence of impaired fertility was seen in rats with exposures (based on C<span class="Sub">max</span>) up to 216 times that observed following a clinical dosage of 1 mg/kg/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="b1923ae3-d6df-4698-8a84-21488616f7e1"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14Â  CLINICAL STUDIES 
</span></h1>
<p class="First"><span class="Bold">Combination Therapy</span><span class="Bold"><br></span>The combination use of stavudine is based on the results of clinical studies in HIV-1-infected patients in double- and triple-combination regimens with other antiretroviral agents.</p>
<p>One of these studies (START 1) was a multicenter, randomized, open-label study comparing stavudine (40 mg twice daily) plus lamivudine plus indinavir to zidovudine plus lamivudine plus indinavir in 202 treatment-naive patients. Both regimens resulted in a similar magnitude of inhibition of HIV-1 RNA levels and increases in CD4<span class="Sup">+</span> cell counts through 48 weeks.</p>
<p><span class="Bold">Monotherapy</span><span class="Bold"><br></span>The efficacy of stavudine was demonstrated in a randomized, double-blind study (AI455-019, conducted 1992-1994) comparing stavudine with zidovudine in 822 patients with a spectrum of HIV-1-related symptoms. The outcome in terms of progression of HIV-1 disease and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was similar for both drugs.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="b598d19a-a34f-4246-82a1-3a1bffdcde66"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">16Â  HOW SUPPLIED 
</span></h1>
<div class="Section">
<a name="section-14.1"></a><p></p>
<h2><span class="Bold">16.2Â Â Â  Oral Solution
</span></h2>
<p class="First">Stavudine for Oral Solution is a dye-free, fruit-flavored powder that provides 1 mg of stavudine per mL of solution upon constitution with water. Directions for solution preparation are included on the product label and in the <span class="Italics"><a href="#b39e7b8f-3af1-45b8-af2e-97778c73f46a">Dosage and Administration (2)</a></span> section of this insert. Stavudine for Oral Solution (NDC No. 64376-133-02) is available in child-resistant containers that provide 200 mL of solution after constitution with water.</p>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15"></a><p></p>
<h1><span class="Bold">STORAGE AND HANDLING 
</span></h1>
<p class="First">Stavudine for Oral Solution should be protected from excessive moisture and stored in tightly closed containers at 20Â°C-25Â°C (68Â°F-77Â°F) [See USP Controlled Room Temperature]. After constitution, store tightly closed containers of Stavudine for Oral Solution in a refrigerator, 2Â°C to 8Â°C (36Â°F to 46Â°F). Discard any unused portion after 30 days.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1><span class="Bold">17Â  INFORMATION FOR PATIENTS 
</span></h1>
<p class="First">See MEDICATION GUIDE.</p>
<div class="Section">
<a name="section-16.1"></a><p></p>
<h2><span class="Bold">17.1Â Â Â  General
</span></h2>
<p class="First">Patients should be advised that stavudine is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and that they may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should be advised to remain under the care of a physician when using stavudine and the importance of adherence to any antiretroviral regimen including those that contain stavudine.</p>
<p>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<dl>
<dt></dt>
<dd><p class="First"><br>â€¢Â Â Â  <span class="Bold">Do not share needles or other injection equipment.</span><br>â€¢Â Â Â  <span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span><br>â€¢Â Â Â  <span class="Bold">Do not have any kind of sex without protection. </span>Always practice safe sex by using a latex or polyurethane condom or other barrier method to lower the chance of sexual contact with semen, vaginal secretions, or blood.<br>â€¢Â Â Â  <span class="Bold">Do not breastfeed.</span> It is not known if stavudine can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in breast milk.</p></dd>
</dl>
<p>Patients should be informed that when stavudine is used in combination with other agents with similar toxicities, the incidence of adverse reactions may be higher than when stavudine is used alone.</p>
<p>Patients should be instructed that if they miss a dose, to take it as soon as possible. If it is almost time for the next dose, skip the missed dose and continue the regular dosing schedule.</p>
<p>Patients should be instructed if they take too much stavudine, they should contact a poison control center or emergency room right away.</p>
<p>Patients should be informed that the Centers for Disease Control and Prevention (CDC) recommend that HIV-infected mothers not nurse newborn infants to reduce the risk of postnatal transmission of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.</p>
</div>
<div class="Section">
<a name="section-16.2"></a><p></p>
<h2><span class="Bold">17.2Â Â Â  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>
</span></h2>
<p class="First">Patients should be informed of the importance of early recognition of symptoms of symptomatic hyperlactatemia or <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis syndrome</span>, which include unexplained <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients in whom these symptoms develop should seek medical attention immediately. Discontinuation of stavudine therapy may be required.</p>
</div>
<div class="Section">
<a name="section-16.3"></a><p></p>
<h2><span class="Bold">17.3Â Â Â  Hepatic Toxicity
</span></h2>
<p class="First">Patients should be informed that an increased risk of hepatotoxicity, which may be fatal, may occur in patients treated with stavudine in combination with didanosine and hydroxyurea. This combination should be avoided.</p>
</div>
<div class="Section">
<a name="section-16.4"></a><p></p>
<h2><span class="Bold">17.4Â Â Â  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>
</span></h2>
<p class="First">Patients should be informed that an important toxicity of stavudine is <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. Patients should be aware that <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> is manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in hands or feet, and that these symptoms should be reported to their physicians. Patients should be counseled that <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> occurs with greatest frequency in patients who have advanced HIV-1 disease or a history of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, and discontinuation of stavudine may be required if toxicity develops.</p>
<p>Caregivers of young children receiving stavudine therapy should be instructed regarding detection and reporting of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
</div>
<div class="Section">
<a name="section-16.5"></a><p></p>
<h2><span class="Bold">17.5Â Â Â  <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>
</span></h2>
<p class="First">Patients should be informed that an increased risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, which may be fatal, may occur in patients treated with the combination of stavudine and didanosine. This combination should be avoided. Patients should be closely monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p>The patient should be instructed to avoid alcohol while taking stavudine. Alcohol may increase the patientâ€™s risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
</div>
<div class="Section">
<a name="section-16.6"></a><p></p>
<h2><span class="Bold">17.6Â Â Â  Fat Redistribution
</span></h2>
<p class="First">Patients should be informed that redistribution or accumulation of body fat may occur in individuals receiving antiretroviral therapy including stavudine. Patients receiving stavudine should be monitored for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>/<span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>. Patients should be routinely questioned about body change related to <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>/<span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-17"></a><p></p>
<h1><span class="Bold">SPL MEDGUIDE 
</span></h1>
<p class="First"><span class="Bold">PHARMACISTS: Detach and dispense the enclosed Medication Guide to each patient.</span></p>
<p><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Stavudine for Oral Solution USP 1mg/mL</span></p>
<p>Read this Medication Guide before you start taking stavudine and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. You and your healthcare provider should talk about your treatment with stavudine before you start taking it and at regular check-ups. You should stay under your healthcare providerâ€™s care when taking stavudine.</p>
<p><span class="Bold">What is the most important information I should know about Stavudine?</span></p>
<p><span class="Bold">Stavudine can cause serious side effects, including:</span><br><span class="Bold">1.</span>Â  <span class="Bold">Build up of acid in your blood (<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>).</span> <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in the hospital. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> may be higher if you:</p>
<ul class="Disc">
<li>have liver problems</li>
<li>are pregnant. There have been <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> reported in pregnant women who get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> after taking stavudine and VIDEX, or stavudine and VIDEX EC (didanosine).</li>
<li>are female</li>
<li>are overweight</li>
<li>have been treated for a long time with other medicines used to treat HIV</li>
</ul>
<p><span class="Bold">It is important to call your healthcare provider right away if you:</span></p>
<ul class="Disc">
<li>feel weak or tired</li>
<li>have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li>have trouble breathing</li>
<li>have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</li>
<li>feel dizzy or light-headed</li>
<li>have a fast or irregular heartbeat</li>
</ul>
<p><span class="Bold">2.Â  Liver problems.</span> Some people (including pregnant women) who have taken stavudine have had serious liver problems. These problems include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>), fat in the liver (steatosis), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to liver problems. Your healthcare provider should check your liver function while you are taking stavudine. You should be especially careful if you have a history of heavy alcohol use or liver problems. Use of stavudine with VIDEX EC or VIDEX (didanosine) may increase your risk for <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
<p><span class="Bold">It is important to call your healthcare provider right away if you have:</span></p>
<ul class="Disc">
<li>yellowing of your skin or the white of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark urine</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the right side of your stomach</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your stomach</li>
<li>easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p><span class="Bold">3.Â  <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>) that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred when stavudine was used with VIDEX EC or VIDEX (didanosine)</span>. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> can happen at any time during your treatment with stavudine.</p>
<p><span class="Bold">It is important to call your healthcare provider right away if you have:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your stomach</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
</ul>
<p><span class="Bold">What is Stavudine?</span></p>
<p>Stavudine is a prescription medicine used with other HIV medicines to treat human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in children and adults. Stavudine belongs to a class of drugs called nucleoside analogues.</p>
<p>Stavudine will not cure your <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. At present there is no cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. Even while taking stavudine, you may continue to have HIV-related illnesses, including <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with other disease-producing organisms. Continue to see your healthcare provider regularly and report any medical problems that occur.</p>
<p><span class="Bold">Who should not take Stavudine?</span></p>
<p><span class="Bold">Do not take Stavudine if you:</span></p>
<ul class="Disc"><li>are allergic to stavudine or any of the ingredients in stavudine. See the end of this Medication Guide for a complete list of the ingredients in stavudine.</li></ul>
<p><span class="Bold">What should I tell my healthcare provider before taking Stavudine?</span></p>
<p>Before you take stavudine, tell your healthcare provider if you:</p>
<ul class="Disc">
<li>have or had liver problems (such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>)</li>
<li>have or had problems with your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</li>
<li>have or had kidney problems</li>
<li>have or had persistent <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the hands or feet (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>)</li>
<li>have <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span></li>
<li>drink alcoholic beverages</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. It is not known if stavudine will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking stavudine. You and your healthcare provider will decide if you should take stavudine while you are pregnant.<p class="First">Pregnancy Registry: There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.</p>
</li>
<li>
<span class="Bold">are breastfeeding or plan to breastfeed. Do not breastfeed.</span> It is not known if stavudine can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.<p class="First"><span class="Bold">Tell your healthcare provider about all the medicines that you take</span>, including prescription and non-prescription medicines, vitamins, or herbal supplements. Stavudine may affect the way other medicines work, and other medicines may affect how stavudine works.</p>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
</li>
<li>COMBIVIR<span class="Sup">Â®</span>, RETROVIR<span class="Sup">Â®</span>, TRIZIVIR<span class="Sup">Â®</span> (zidovudine or AZT)</li>
<li>VIDEX<span class="Sup">Â®</span> or VIDEX EC<span class="Sup">Â®</span> (didanosine)</li>
<li>ADRIAMYCIN<span class="Sup">Â®</span>, RUBEX<span class="Sup">Â®</span> (doxorubicin)</li>
<li>COPEGUS<span class="Sup">Â®</span>, REBETOL<span class="Sup">Â®</span>, RIBASPHERE<span class="Sup">Â®</span>, RIBAVIRIN<span class="Sup">Â®</span>, VIRAZOLE<span class="Sup">Â®</span> (ribavirin)</li>
<li>ROFERON-A<span class="Sup">Â®</span>, INTRON-A<span class="Sup">Â®</span>, and others (interferon)</li>
<li>HYDREA<span class="Sup">Â®</span>, DROXIA<span class="Sup">Â®</span> (hydroxyurea)</li>
</ul>
<p>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
<p>Ask your healthcare provider if you are not sure if you take one of the medicines listed above.</p>
<p><span class="Bold">How should I take Stavudine?</span></p>
<ul class="Disc">
<li>Take stavudine exactly as your healthcare provider tells you to take it.</li>
<li>Your healthcare provider will tell you how much stavudine to take and when to take it.</li>
<li>If your child will be taking stavudine, your childâ€™s healthcare provider should give you instructions on how to give this medicine. If your child is taking stavudine oral solution, shake the bottle well before measuring each dose.</li>
<li>Your healthcare provider may change your dose. Do not change your dose of stavudine without talking to your healthcare provider.</li>
<li>Stavudine may be taken with or without food.</li>
<li>Try not to miss a dose, but if you do, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule.</li>
<li>Some medicines may require your healthcare provider to monitor your therapy or change your therapy. Check with your healthcare provider.</li>
<li>If your kidneys are not working well, your healthcare provider will need to do regular blood and urine tests to check how they are working while you take stavudine. Your healthcare provider may also lower your dosage of stavudine if your kidneys are not working well.</li>
<li>
<span class="Bold">If you take too much stavudine</span>, contact a poison control center or emergency room right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking Stavudine?</span></p>
<ul class="Disc"><li>
<span class="Bold">Alcohol. You should avoid drinking alcohol while taking stavudine</span>. Alcohol may increase your risk of getting <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>) or may damage your liver.</li></ul>
<p><span class="Bold">What are the possible side effects of Stavudine?</span></p>
<p><span class="Bold">Stavudine can cause serious side effects including:</span></p>
<ul class="Disc">
<li>Stavudine can cause <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, liver problems, and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. See <span class="Bold">â€œWhat is the most important information I should know about Stavudine?â€?</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic symptoms</span>. Symptoms include: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of your legs, feet, arms, or hands (motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>) and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your hands or feet (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>)</span>. These problems can happen more often in people who have advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>, have a history of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, or in people who take other medicines that also are associated with <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> including didanosine. In some cases, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> may temporarily worsen after you stop taking stavudine. <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> can be difficult to notice in children who take stavudine. Ask your childâ€™s healthcare provider for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> in children.</li>
</ul>
<p><span class="Bold">It is important to call your healthcare provider right away if you have:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in your hands or feet</li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your hands or feet</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in your legs, feet, arms, or hands</li>
<li>
<span class="Bold">Changes in body fat (fat redistribution).</span> Changes in body fat (<span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>) have been seen in some people taking HIV medicines including stavudine. Loss of body fat (<span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>) happens more often in people who take stavudine than in people who take other similar HIV medicines.<br>These changes may include:</li>
</ul>
<ul class="Disc">
<li>more fat in or around your<dl>
<dt>-</dt>
<dd>trunk</dd>
<dt>-</dt>
<dd>upper back and neck (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>)</dd>
<dt>-</dt>
<dd>breast or chest</dd>
</dl>
</li>
<li>loss of fat in your<dl>
<dt>-</dt>
<dd>legs</dd>
<dt>-</dt>
<dd>arms</dd>
<dt>-</dt>
<dd>face</dd>
</dl>
</li>
</ul>
<p><span class="Bold">Your healthcare provider will monitor you for changes in your body fat</span>. It is important to tell your healthcare provider if you notice any of these changes.</p>
<ul class="Disc">
<li>Changes in your immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span>). Your immune system may begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been in your body for a long time. Tell your healthcare provider if you start having new or worse symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after you start taking HIV medicine.<p class="First">The most common side effects of stavudine include:</p>
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of stavudine. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Stavudine?</span></p>
<ul class="Disc"><li><span class="Italics">Oral solution:</span></li></ul>
<dl>
<dt></dt>
<dd><p class="First"> -Store Stavudine oral solution in the refrigerator at 36Â°F to 46Â°F (2Â°C to 8Â°C)</p></dd>
<dt></dt>
<dd><p class="First"> -Store Stavudine oral solution in a tightly closed container.</p></dd>
<dt></dt>
<dd><p class="First"> -Throw away any unused medicine after 30 days.</p></dd>
</dl>
<p><span class="Bold">Keep Stavudine and all medicines out of the reach of children and pets.</span></p>
<p><span class="Bold">General Information about the safe and effective use of Stavudine.</span></p>
<p>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<ul class="Disc">
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection. </span>Always practice safe sex by using a latex or polyurethane condom or other barrier method to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use stavudine for a condition for which it was not prescribed. Do not give stavudine to other people, even if they have the same symptoms as you have. It may harm them. Do not keep medicine that is out of date or that you no longer need. Dispose of unused medicines through community take-back disposal programs when available or place stavudine in an unrecognizable closed container in the household trash.</p>
<p>This Medication Guide summarizes the most important information about stavudine. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about stavudine that is written for health professionals. For more information, go to www.cipla.com or call at 1-866-604-3268.</p>
<p><span class="Bold">What are the ingredients in Stavudine?</span></p>
<p><span class="Bold">Active Ingredient:</span> stavudine<br><span class="Bold">Inactive Ingredients:</span><span class="Bold"><br></span>Stavudine for Oral Solution: carboxymethyl cellulose sodium, mannitol, methylparaben, propylparaben, sodium saccharin, and strawberry cream flavour.</p>
<p>Other brands listed are the registered trademarks of their respective owners and are not of Cipla Ltd. or Boca Pharmacal, LLC.</p>
<p>Revised October 2013</p>
<p>Manufactured for:<br><span class="Bold">Boca Pharmacal, LLC</span><span class="Bold"><br></span>Coral Springs, FL 33065<br><a href="http://www.bocapharmacal.com/">www.bocapharmacal.com</a><br>1-800-354-8460</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First"><span class="Bold">Label</span><br></p>
<p><span class="Bold"><img alt="a1ac2cfb-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=259fbf19-ad1a-424f-873a-ba12e42b9315&amp;name=a1ac2cfb-figure-02.jpg"></span><br></p>
<p><span class="Bold">Carton</span><br></p>
<div class="Figure"><img alt="a1ac2cfb-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=259fbf19-ad1a-424f-873a-ba12e42b9315&amp;name=a1ac2cfb-figure-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>STAVUDINEÂ 		
					</strong><br><span class="contentTableReg">stavudine solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64376-133</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>STAVUDINE</strong> (STAVUDINE) </td>
<td class="formItem">STAVUDINE</td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM DIHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">STRAWBERRY (Strawberry Cream) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64376-133-02</td>
<td class="formItem">200 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078030</td>
<td class="formItem">08/17/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Boca Pharmacal, LLC
							(170266089)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Cipla Ltd. (650138746)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a1ac2cfb-8d6f-4a81-91b0-9239bf4ebf1c</div>
<div>Set id: 259fbf19-ad1a-424f-873a-ba12e42b9315</div>
<div>Version: 2</div>
<div>Effective Time: 20131002</div>
</div>
</div>Â <div class="DistributorName">Boca Pharmacal, LLC</div></p>
</body></html>
